Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
The SUSTAIN 6 trial demonstrated a 26% reduction in major adverse cardiovascular events in patients with type 2 diabetes
Downstream analysis was conducted with the compassR package and differential metabolic states were determined with a Wilcoxon Rank Sum Test on the Compass reactions
In one trial, participants taking 5 mg lost 15% of their body weight, those taking 10 mg lost 19.5%, and those taking 15 mg lost 20.9% after 72 weeks
52 GalloS.GattiS.SalaV.AlbanoR.CostelliP.CasanovaE.et al (2014a)
In the SUSTAIN clinical trial program evaluating Ozempic for type 2 diabetes, injection site reactions were reported in 1.2-1.4% of patients receiving semaglutide compared to 0.7% receiving placebo
US$ 22.54
US$ 23.73
US$ 24.94
US$ 24.97
US$ 26.28
